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Abstract Evaluation of short- and long-term clinical fea-
sibility and exploration of limitations and advantages of a
new automatic speaking valve (ASV) for laryngectomized
patients with integrated HME, the Provox FreeHands
FlexiVoice (FlexiVoice). This ASV not only enables
automatic, but also manual closure of the valve. A multi-
center, prospective clinical study in 40 laryngectomized
patients was conducted. Participants were asked to use the
FlexiVoice for 26 weeks. The primary outcome measure
was long-term compliance. Secondary outcome measures
were: patient preference, hours of FlexiVoice use, device
life of adhesive, voice and speech quality, and quality of
life. After 26 weeks, 15 patients (37.5 %) were using the
FlexiVoice on a daily basis, for a mean of 12.64 h/day
(SD ± 5.03). Ten patients (25 %) were using the device on
a non-daily basis, for a mean of 3.76 h/day (SD ± 2.07).
The remaining 15 patients (37.5 %) discontinued using the
FlexiVoice. Sixty percent of the 25 long-term users applied
both automatic and manual closure of the valve. Unpre-
dictable fixation of the adhesive was the main reason for
discontinuing or not using the FlexiVoice on a daily basis.
Overall, 18 patients (45 %) preferred the FlexiVoice, 16
patients (40 %) their usual HME, 3 patients (7.5 %) their
usual ASV, 1 patient (2.5 %) preferred no device at all, and
in 2 patients preference was not recorded. The minor
technical issues identified could be corrected. The Provox
FreeHands FlexiVoice appears to be a useful ASV, which
allows for hands-free speech in a larger proportion of
laryngectomized patients in the present cohort. The addi-
tional manual closure option of the device is beneficial for
maintaining the adhesive seal longer.
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Introduction
Total laryngectomy (TL) results in significant anatomical
changes. The alimentary and respiratory tracts are sepa-
rated and a permanent stoma is created in the neck [1].
To compensate for the loss of the voice box, currently
primary insertion of a tracheoesophageal voice prosthesis
is the gold standard for restoring pulmonary-driven
speech [2]. To compensate for the functional loss of the
upper respiratory tract and to prevent and/or treat pul-
monary problems, such as excessive coughing and mucus
production, continuous use of heat and moisture
exchanger (HME) has proven to be effective [3–5].
Speaking with a voice prosthesis requires airtight
occlusion of the stoma with a finger to divert the pul-
monary air into the pharyngoesophageal segment or
neoglottis, where mucosal vibrations produce the sound
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for speech. Airtight stoma occlusion has become easier
after the development of specialized HMEs, which
improve maximum phonation time and dynamic loudness
range and thus compliance rate [6]. However, with these
HMEs, it is still necessary to use a finger to occlude the
stoma for speech production. To overcome this drawback
of tracheoesophageal speech and to obtain hands-free
speech, automatic speaking valves (ASVs) have been
developed. These devices contain a flexible membrane
that stays open during normal calm breathing, but closes
through the natural increase in air pressure when
speaking is initiated [7, 8]. Several ASVs are presently
available. The first were the Blom Singer and Bivona
tracheostoma valves in the eighties and nineties of the
last century [8–10]. Later, several other valves became
available, such as the Eska-Herrmann and ADEVA
valves [11, 12]. In 2003, the Provox FreeHands HME
(further called FreeHands; Atos Medical, Ho¨rby, Sweden)
was introduced, which was the first automatic speaking
valve with an integrated HME for simultaneous pul-
monary rehabilitation [7]. In a long-term (6 months)
study, the success rate (defined as patients using this
ASV on a daily basis) was 19 % [13]. Additionally,
57 % of patients in this study used the device on a non-
daily basis at special occasions, such as during shopping
or social activities [13]. The main reason for not using
the FreeHands on a daily basis was the unpre-
dictable fixation of the adhesive to the peristomal skin.
This is the main drawback for all ASVs. For a consid-
erable number of patients, it can be problematic to obtain
a good and long-lasting seal of the adhesive to withstand
the pressure necessary for speaking [14–17].
To further improve patient friendliness and compliance
of automatic speech, a new automatic speaking valve was
developed, the Provox FreeHands FlexiVoice (further
called FlexiVoice; Atos Medical AB, Ho¨rby, Sweden).
This new ASV contains a renewed mechanism to lock
and unlock the speaking membrane. The air pressure
needed to close the membrane is lower than in the earlier
FreeHands device, because the available membranes are
more flexible. Moreover, there is a novel option to
alternatively occlude the device manually: a front open-
ing also allows speech through finger occlusion of the
device, even when the membrane is locked, e.g., during
physical exertion. Lastly, the coughing mechanism is
adapted, which also allows easy repositioning of the
valve after coughing.
The objective of this prospective clinical study is to
evaluate the short- and long-term feasibility of the
FlexiVoice, in combination with the currently available
attachments, and to explore its limitations and
advantages.
Methods
The study was carried out at two tertiary care cancer cen-
ters. Inclusion criteria were: TL, 18 years or older, use of
an HME and/or ASV, use of a voice prosthesis irrespective
of the voice quality, minimum of 3 months after TL and/or
postoperative (chemo-) radiotherapy. Exclusion criteria
were: inability to remove or operate the FlexiVoice, active
recurrent or metastatic disease, inability to understand the
patient information, to give informed consent, and/or to
complete diaries. The study was performed according to
the protocol approved by the institutional review boards
and all patients were enrolled in the study between May
2014 and August 2014. Signed informed consent was
obtained from all participants.
The FlexiVoice is shown in Fig. 1 (left). It combines
pulmonary rehabilitation using an HME, with voice reha-
bilitation using an ASV, which also facilitates manual
occlusion. The device is attached in front of the stoma of a
laryngectomized patient, who is using a voice prosthesis
for speech. There are different attachment options for the
subjects to choose from (various stoma adhesives, laryn-
gectomy tubes and buttons). The base of the device is the
HME cassette and the speaking valve is anchored on top of
that HME cassette. The speaking valve has a front opening
and an internal flexible membrane. When the patient starts
to speak, the natural increase in exhalation airflow closes
the membrane. The exhaled air is thus diverted through the
voice prosthesis, which allows hands-free tracheoe-
sophageal speech. Alternatively, the patient can choose to
occlude the opening in the front with his/her finger to
speak. Rotating the top of the device moves the FlexiVoice
into the ‘locked mode’, or into the ‘automatic speaking
mode’ (Fig. 1, middle left). In ‘locked mode’, the mem-
brane is prevented from closing with a hook grabbing a
ring at the backside of the membrane (Fig. 1, middle right).
Thereby, the patient is ensured of unrestricted and com-
fortable breathing during physical exertion, still allowing
manual occlusion for speech. There are three versions of
the speaking valve, each with a different flexibility/strength
of the membrane: light, medium and strong. When
coughing is needed, the membrane pops out through the
front opening and the patient can push the membrane back
manually. There is an optional arch that can be attached on
top of the device to prevent the front opening of being
occluded by clothing (Fig. 1, right).
After inclusion, patients used the FlexiVoice for the
duration of a maximum of 6 months. The primary objective
was to assess long-term compliance, based on various
aspects of the ASV addressed in study-specific question-
naires. Secondary outcome measures were: patient prefer-
ence, hours of FlexiVoice use, device life of adhesive,
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voice and speech quality and quality of life. The ques-
tionnaires were completed at the time of inclusion, after
4 weeks and after 26 weeks.
The study specific questionnaires addressed the use of
adhesive, effort needed to speak, noises produced by the
FlexiVoice, coughing mechanism, appearance, functioning
of the membrane, use of the ‘locked mode’/‘automatic
speaking mode’, manual occlusion, device life of adhesive,
voice quality, speech quality and intelligibility. Addition-
ally, patients rated satisfaction regarding the FlexiVoice,
their usual ASV/HME (if applicable), the device life of
their adhesive, and their voice quality on a 10-cm Numeric
Rating Scale (NRS) (0 = worst and 10 = best).
Quality of life was assessed using the EuroQOL-5
Dimension-5 Level questionnaire (EQ5D5L). This instru-
ment is validated using scores in five health-care dimen-
sions (mobility, self-care, daily activities, pain/discomfort
and anguish/depression) and a 100-mm VAS [18]. Voice
and speech quality assessment consisted of reading a text,
numbering breathing pauses, maximum phonation time
(vowel /a/ and counting) and dynamic loudness range (with
calibrated decibel meter). During the study period, patients
kept a diary twice for 3 days in the week before each
follow-up visit to record daily hours of FlexiVoice use. At
the end of the study, patients were asked to complete
comparative questionnaires. Patients were asked to com-
pare the FlexiVoice with the usual ASV and/or HME and
to answer questions regarding preference and future use.
Patients were contacted by telephone 2 weeks after inclu-
sion and at monthly intervals until 26 weeks of follow-up.
If needed, additional practical support from the speech
pathologist or the study coordinator was offered. Figure 2
provides an overview of the study design.
Statistics
As this was deemed to be an uncomplicated feasibility
study in patients familiar with the use of peristomal
adhesives and HME devices and no risks associated with
participation in the study were expected, the dropout rate
was estimated to be\5 %. Statistical analyses were con-
ducted using IBM SPSS 22.0. Frequencies were
explored using the Kolmogorov–Smirnov test. Parametri-
cally distributed data are shown as mean ± standard
deviation and analyzed using the paired T test. Non-para-
metric data are presented as median (interquartile range)
and were analyzed using the Wilcoxon signed rank test.
The Likert scales rendered ordinal data from three related
samples. This data was analyzed using the Friedman test. If
the groups differed significantly, a Wilcoxon signed rank
test was used to determine which groups were different. A
p value\0.05 is considered to be significant.
Results
In total, 41 laryngectomized patients were entered in the
study, 21 in one institute and 20 in the other. One patient
subsequently had to be excluded from the study and further
analysis, because the language barrier was larger than
anticipated and he did not understand the patient infor-
mation. Thus, the remaining 40 patients, 36 males and 4
females, were included for analysis. Patient demographics
and clinical information are provided in Table 1. At
baseline, 27 patients were not using an ASV (67.5 %), 12
patients were using an ASV in combination with an HME
and (30 %) 1 patient was using only an ASV (2.5 %), also
during the night (all ASVs were the FreeHands [7]). Of
those 13 ASV users (32.5 %), 8 patients were using the
ASV on a daily basis (20 %) and 5 patients on a non-daily
basis (12.5 %). The mean ASV use of the eight daily users
was 13.25 h and of the five non-daily users 3.26 h. Of the
27 non-users, 19 (70 % did have experience with an ASV
before entering the study and 6 (15 %) did not (data in 2
patients was missing). Most ASV users were using one of
the ‘stronger’ adhesives, such as the Provox StabiliBase
adhesive (Atos Medical AB, Ho¨rby, Sweden). The self-
reported median device life of the adhesive was 19 h
Fig. 1 Left Provox FreeHands FlexiVoice. The heat and moisture
exchanger (HME) is attached and the flexible membrane is closed.
Middle left ‘automatic speaking mode’. Middle right ‘locked mode’:
the patient can rotate the top of the device and the membrane is
locked by a hook that grabs a ring at the backside of the membrane.
Right the arch is attached. It prevents the front opening being
occluded by clothing (left 3 pictures by courtesy of Atos Medical)
Eur Arch Otorhinolaryngol (2017) 274:1005–1013 1007
123
(range 1–168) when using an ASV (n = 12; data in 1
patient was missing). Patients’ satisfaction regarding
adhesive device life when using the ASV was rated 7.16 on
a scale 1–10 (NRS; SD ± 2.35; n = 11). This information
was missing in two patients. For the non-ASV users, the
median device life of the adhesive was 24 h (range
6–168 h; n = 26, data missing in 1 patient).
Assessment at 4 weeks
At the 4-week follow-up, 36 patients were still in the study
and 4 had stopped using the FlexiVoice. Nineteen of the
original 40 patients (47.5 %) used the FlexiVoice on a
daily basis, for a mean of 10.87 h/day (SD ± 4.67; n = 18;
missing data in 1). Seventeen of the original 40 patients
(42.5 %) used the FlexiVoice on a non-daily basis, for a
mean of 6.82 h/day (SD ± 6.12; missing data n = 1). The
reasons for not using the FlexiVoice on a daily basis are
shown in Table 2. Most common were unpredictable fixa-
tion of the peristomal adhesive (n = 3) and familiarity of
the usual HME/ASV (n = 3). Furthermore, for the four
patients, who discontinued between inclusion and the
4-week follow-up, the reasons given are also summarized
in Table 2.
Assessment at 26 weeks
At 26 weeks, 25 patients still used the FlexiVoice, whereas
the remaining 11 patients had discontinued its use. Fifteen
Fig. 2 Study flowchart





Age at TL Mean 56.3 years (SD ± 9.4)
Age at entry Median 63.5 years (SD ± 8.91)
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of these 25 patients (37.5 % of the original 40 patients)
used the FlexiVoice on a daily basis, for a mean of
12.64 h/day (SD ± 5.03; n = 14; missing data n = 1).
Ten patients (25 % of the original 40 patients) used the
device on a non-daily basis, for a mean of 3.76 h/day
(SD ± 2.07; n = 6; missing data n = 4). The type of
surgery (standard TL versus pharyngeal reconstruction) did
not influence ASV use. Unpredictable fixation of the
adhesive was the main reason (n = 4) for not using the
FlexiVoice on a daily basis at 26 weeks follow-up. All
reasons are shown in Table 2, as well as the reasons for
discontinuing between 4 and 26 weeks. Actual FlexiVoice
use in the ten non-daily users was: 5–6 days/week (n = 1),
3–4 days/week (n = 4), 1–2 days/week (n = 2), 1–2 day-
s/month (n = 1) and less than once per month (n = 2).
Occasions when using the FlexiVoice in this non-daily user
group are also given in Table 2.
Thus, in total, 15 patients decided to end the study
earlier than planned, of whom 2 patients did use an ASV at
baseline (and went back to that) and 13 patients did not use
an ASV at baseline. An overview of patient numbers,
compliance and rates regarding hands-free speech at dif-
ferent moments in the study is given in Figs. 3 and 4.
With respect to the attachment of the FlexiVoice to the
stoma at 26 weeks, of the 25 FlexiVoice users 13 were
using the StabiliBase adhesive to attach the FlexiVoice, 4
FlexiDerm, 3 OptiDerm, 3 StabiliBase OptiDerm, 1 Reg-
ular, 1 XtraBase, 3 LaryTube and 2 LaryButton (more
options per patient possible; all adhesives/devices are from
Atos Medical AB, Ho¨rby, Sweden). The self-reported
median daily device life of the adhesive was 8 h (range
0.25–168), when using the FlexiVoice (n = 23; 2 patients
were not using an adhesive, but a laryngectomy button).
Patients’ satisfaction regarding adhesive device life with
the FlexiVoice was rated on average 6.46 (NRS; SD 2.61;
n = 23). Four of 11 patients (36 %), who used an ASV at
baseline, changed their choice of adhesive(s), and 8 of 14
patients (57 %), who did not use an ASV at baseline, also
changed their choice of adhesive(s).
With regard to the practical aspects of the FlexiVoice,
patients were, e.g., asked to indicate if the membrane was
popping out while coughing. Almost all patients answered
affirmative and all patients found it easy to push the
membrane back. When asked if the membrane sometimes
closed unintentionally, 12 patients answered in the affir-
mative and 13 patients answered as negative. This hap-
pened mostly when patients were physically active
(n = 11). Seventeen of 25 patients (68 %) did use the
‘locked mode’ with a median of 1.5 times per day (range
0–10). All patients used automatic occlusion and 15 of 25
long-term users (60 %) used both automatic occlusion and
manual occlusion. The main reasons for using manual
occlusion were: loosening of the adhesive makes hands-
free speech impossible, but still allows speech with manual
occlusion (n = 8), and the voice is louder (n = 3).
Seventeen of 25 patients indicated good intelligibility when
using the FlexiVoice in automatic speaking mode, 2 found
the intelligibility reasonable, 4 moderate and 2 poor. No
Table 2 Reasons for discontinuing the study and not using FlexiVoice on a daily basis, and occasions when using FlexiVoice in the latter non-
daily user group
Reasons for discontinuing the study between inclusion and 4 weeksa
Unpredictable adhesion of adhesive (n = 1); excessive mucus (already at baseline; n = 1); voice prosthesis problem (n = 1); recurrent
disease (n = 1)
Reasons for not using FlexiVoice on a daily basis at 4 weeksa
Unpredictable adhesion of adhesive (n = 3); familiarity with usual HME/ASV (n = 3); less easy voicing (n = 3); ‘‘FlexiVoice cannot be
used without HME’’ (n = 2); skin irritation with adhesive (n = 1); uncomfortable breathing resistance (n = 1); more mucus (n = 1);
problem with voice prosthesis (n = 1); high T-shirt difficulty (n = 1); mostly using esophageal speech (n = 1); air leakage with manual
occlusion (n = 1); unintentional closing membrane (n = 1); when home alone, ASV not necessary (n = 1)
Reasons for discontinuing the study between 4 and 26 weeksa
Unpredictable adhesion of adhesive (n = 6); too high breathing resistance (n = 6); soft voice (n = 2); too easy closing membrane (n = 2);
usual ASV easier (n = 2); not easy with certain clothes (n = 1); too much speaking effort (n = 1); annoying sounds (n = 1); excessive
mucus (already at baseline; n = 1); poor intelligibility (n = 1)
Reasons for not using the FlexiVoice on a daily basis at 26 weeksa
Unpredictable adhesion of adhesive (n = 4); more mucus (n = 2); uncomfortable breathing resistance (n = 2); soft voice (n = 2);
preference for usual HME (n = 2); less easy voicing (n = 1); when home alone ASV not necessary (n = 1); too fast popping out membrane
(n = 1); too loose arch (n = 1)
Occasions when using FlexiVoice in the non-daily user group at 26 weeksa
At home (n = 9); during social activities (n = 6); in special situations [e.g., when driving a car, on a quiet day, only during patient
counseling (e.g., one of the less then once a month patients) (n = 3)]; during the whole day (n = 2); at the work place (n = 1)
HME heat and moisture exchanger, ASV automatic speaking valve
a More options per patient possible
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significant differences in quality of life (according to the
EQ5D5L) were found between baseline, at 4 weeks and at
26 weeks (data not shown). There were also no significant
differences of the objective voice parameters assessed
between baseline and 26 weeks follow-up (see Table 3).
Comparison with usual ASV
At 26 weeks, 11 patients did compare the FlexiVoice with
their usual ASV (in all patients, the FreeHands). Regarding
the coughing mechanism, six patients preferred the
coughing mechanism of the FlexiVoice and five expressed
no preference. Regarding the overall voice quality, five
patients preferred the FlexiVoice, five had no preference
and one preferred the FreeHands. Regarding speaking
effort, five patients preferred the FlexiVoice and six
expressed no preference. Membrane-closing noise was
reportedly less with the FlexiVoice in four patients, with
the FreeHands also in four and similar in three patients.
Furthermore, 4 of these 11 ASV patients reported that they
could speak longer on one intake of breath with the Flex-
iVoice, whereas 7 patients expressed no difference in this
respect. Regarding appearance, eight patients preferred the
FlexiVoice and three had no cosmetic preference. Overall,
one of these 11 patients preferred to stay with his original
ASV.
With regard to overall stoma occlusion preference at
26 weeks, 18 patients preferred the FlexiVoice (45 %), 16
(40 %) their usual HME, 3 (7.5 %) their usual ASV and 1
(2.5 %) no device at all. The preference in the two patients
(5 %), who stopped before the 4 weeks assessment because
of recurrent disease/voice prosthesis problem, was not
recorded. Figure 5 shows the preferences. Finally, regard-
ing future use, 16 out of 40 patients (40 %) would continue
to use the FlexiVoice daily, 8 patients reported that they
would use the FlexiVoice on a non-daily basis (20 %) and
16 patients would not continue with the FlexiVoice.
During this study, 17 clinical and device-related events
were registered. One event concerned aspiration of the
voice prosthesis, which was not FlexiVoice related (voice
prosthesis was retrieved from the trachea; no further mor-
bidity). There were 13 device-related events, most of which
(n = 6) concerned the arch that fitted too loosely on the
FlexiVoice. Based on these reports the arch underwent a
redesign, which solved this issue. Another issue (n = 3)
was air leakage from the device when closed manually,
which was solved by adapting the attachment of the HME
to the FlexiVoice. The other four concerned membrane
issues, which also led to minor design changes solving this.
The remaining three registered events concerned one
patient, who complained twice about excessive moisture
collection in the device, and one patient, who complained














Fig. 4 Compliance rates regarding hands-free speech (n = 40)
Table 3 Objective voice assessment: hands-free speech parameters
at baseline and 26 weeks [median (range)]
Baseline (n = 13) 26 weeks (n = 23*)
Breathing pauses (n) 23 (16–68) 24 (9–66)
Total length of text (min) 1:19 (1.05–1.58) 1:14 (0.56–2.37)
Max phonation time (s)
Prolonged /a/ 7.30 (2.70–30.40) 7.58 (2.57–32.35)
Counting 11.1 (3.90–19.10) 11.76 (2.50–45.00)
Dynamic loudness range (dB)
Softest 58 (42–70) 58 (51–69)
Comfortable 67.3 (62–74) 66 (55–77)
Loudest 77 (73–84) 79 (70–92)
There are no significant differences between the baseline and
26 weeks
* Two patients did not complete the voice assessment or not all items,
because one could not read and the other could not read Dutch, and
his adhesive did not last long
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about excessive mucus production (already present at
baseline).
Discussion
This prospective clinical feasibility study on the evaluation
of the Provox FreeHands FlexiVoice, a new ASV for
laryngectomized patients using prosthetic voice, shows
favorable results. The daily use of hands-free speech in this
cohort increased from 20 % (8/40) at baseline to 37.5 %
(15/40) at 26 weeks follow-up, with 10 of the original 13
FreeHands users switching to the new FlexiVoice. More-
over, besides the original five non-daily FreeHands users,
there were five additional non-daily users for a total of ten
patients (12.5 % at baseline compared to 25 % at
26 weeks), who used/converted to the new FlexiVoice
device. Thus, for almost two-thirds of the patients, the
FlexiVoice is a valuable option, whereas one-third of the
patients remain fully dependent on finger occlusion. The
expectation that the new features/adaptations of this new
automatic speaking valve would result in an increased
proportion of patients able to use hands-free speech seems
to be met. An interesting observation is that the number of
hours of ASV use was not different between both devices.
Daily ASV users applied the device 13.25 h per day at
baseline, 10.87 h at 4 weeks and 12.64 h at 26 weeks. For
the non-daily users, these numbers were 3.26, 6.82 and
3.76 h, respectively. This is in line with the fact that daily
users tend to apply the ASV only during daytime and non-
daily users only at special occasions.
Several factors could have contributed to this increased
hands-free speaking rate. At the end of the study, 60 % of
the FlexiVoice users (15 out of 25 patients) used automatic
occlusion in combination with manual occlusion and the
main reason for switching to manual occlusion was the
unpredictable fixation of the peristomal adhesive. The
advantage of this new feature of the FlexiVoice is that,
when the adhesive starts loosening, it is still possible to use
the device by occluding the opening in the front with a
finger, which maintains the seal somewhat longer, obviat-
ing the immediate need to switch back to a normal HME
and/or change the adhesive. An effective coughing mech-
anism is another important aspect of hands-free speech,
both for relieving the tracheal pressure and maintaining a
good seal of the adhesive. In almost all patients, the
membrane popped out on coughing and it was easy to push
the membrane back; this might have been an additional
reason for patients to continue using the FlexiVoice. It
cannot be excluded, though, that an important reason for
this increased use might have been that the StabiliBase and
StabiliBase OptiDerm adhesives, with a more stable and
more anatomically shaped conical base, were popular
adhesives in this study population and that these were not
yet available during previous studies evaluating hands-free
speech [19]. Lastly, the increased number of patients using
hands-free speech, in part, also could have been an effect of
the renewed attention to an ASV some time later during the
follow-up, something that should be kept in mind during
regular aftercare of laryngectomized patients. A failure to
acquire hands-free speech early on might still be
correctable later.
There are several comparable studies on ASVs. The
study of Op de Coul et al. (2005) evaluating the FreeHands
device describes a higher overall compliance rate of 76 %
than the 62.5 % (daily and non-daily users) in the present
study [13]. However, the daily use of hands-free speech has
doubled from 19 to 37.5 % in the present study, as has the
number of h/day from a median of 5 h/day with FreeHands
to more than 12 h/day with the FlexiVoice. In their study
on the FreeHands device in 14 patients, Tervonen et al.
found daily use in only 7 %, non-daily use in 86 % and
non-use in 7 % [20]. These figures are again different from
the ones found in the present study, but the numbers of
patients in the Tervonen study are quite low, and there was
a selection bias because only patients with a clear voice
when using an HME were included [20]. In the present
study, no such selection was made and also patients with
less clear voices were represented. The heterogeneity of
our patient sample (with 32 standard TLs, 6 pharynx
reconstructions and 1 gastric pull-up) certainly results in a
wide range of voice qualities, but this in fact did not
influence long-term ASV use: reconstructed patients did as
good as standard TL patients in this respect. Schwarz et al.
described an acceptance rate of 62 % of patients using the
device for at least 2 h per day during 4 weeks [21]. Such
early results might not be that relevant, because in our
study, compliance rate regarding daily use dropped from
47.5 % after 4 weeks to 37.5 % after 26 weeks, and the
overall compliance dropped from 90 % at 4 weeks to
62.5 % at 26 weeks. To properly assess the compliance
regarding a complicated device such as an ASV, a longer
than a 4-week follow-up period is thus needed to provide
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%





Fig. 5 Preference after 26 weeks (n = 40). ASV automatic speaking
valve, HME heat and moisture exchanger
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relevant information. The study of Lorenz et al. on the
FreeHands device in 24 patients does have a similar fol-
low-up time as the present study (6 months), and the results
are quite comparable with 42 % daily users and 29 % non-
daily users [22]. However, the mean number of hours in the
daily users, just like in the Op de Coul study, was also
lower (8.4 h) than with the new FlexiVoice. Furthermore,
the firsthand comparison of the FreeHands and FlexiVoice,
possible in the present study for 11 patients, showed
interesting differences, also supporting the assumption that
the new design features of the FlexiVoice indeed improved
its usability. The reported differences in favor of the
FlexiVoice were less speaking effort, better overall voice
quality, better appearance, easier and less noisy coughing
mechanism and less noisy closing of the speaking
membrane.
The key success factor of hands-free speech is main-
taining the seal of the adhesive [7–9, 19, 21, 23]. It is
important to realize that, as reported in the results, the
median device life of the adhesive among ASV users at
baseline was 19 h (range 1–168), whereas this was 8 h
(range 0.25–168) reported in diaries after 26 weeks using
the FlexiVoice. A possible explanation for this consider-
able difference in adhesive device life is that the patients,
who used an ASV at baseline, were successful because of
their excellent adhesive seal. Nevertheless, this study also
shows once more that difficulties with adhesion of the
adhesive to the skin are still a limiting factor, despite the
easier closing of the more flexible/less strong membranes
and the wider range of adhesives available for laryngec-
tomized patients. More research and product development
are thus needed to further improve peristomal attachment.
No significant differences in objective voice assessment
were found between baseline, after 4 weeks and after
26 weeks, which shows that patients using the FlexiVoice
are able to produce the same voice and speech quality
compared to their baseline measurement with FreeHands as
well as with HME. This is in contrast with the Op de Coul
study, in which several voice parameters, such as maxi-
mum phonation time and dynamic loudness range, were
significantly better when speaking with the HME [13]. The
lack of such difference in the present cohort seems to
further confirm the design improvements of the FlexiVoice.
The present study has some limitations. Although the
only inclusion criterion was the ability to tolerate an HME,
there still might have been a selection bias toward more
motivated patients. Furthermore, some of the variables that
(also) might influence hours of use of the FlexiVoice were
not collected. In hindsight, it would have been interesting
to not only let the patients report daily hours of FlexiVoice
use in diaries, but also to ask the patients to give insight
into the intensity of speech during the day. Also, infor-
mation of stoma dimensions and local anatomy might have
been of value to correlate duration of adhesive seal and
thus hands-free speaking time [23]. Another limitation
could be that for experienced ASV users, it is easier to
handle a new ASV. However, they were willing to switch,
only if the new device was really perceived as an
improvement. Otherwise, they tended to stay with their
original device. The fact that 10 of the original 13 ASV
users did switch to the new ASV suggests that this limi-
tation does not play a major role in this cohort.
In conclusion, the Provox FreeHands FlexiVoice is a
useful ASV, which seems to allow for hands-free speech in
a larger proportion of laryngectomized patients in the
present cohort. The additional manual closure option of the
FlexiVoice is experienced as beneficial for maintaining the
adhesive seal longer.
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